董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Richard Christopher | 男 | Chief Executive Officer and Director | 57 | 61.25万美元 | 41.50 | 2026-01-27 |
| Bal Bhullar | 女 | Independent Director | 57 | 未披露 | 2.40 | 2026-01-27 |
| Christopher Bunka | 男 | Chairman and Independent Director | 65 | 28.08万美元 | 84.03 | 2026-01-27 |
| John Docherty | 男 | Chief Science Officer,Director and President | 57 | 52.35万美元 | 37.03 | 2026-01-27 |
| Nicholas Baxter | 男 | Independent Director | 72 | 5.54万美元 | 7.40 | 2026-01-27 |
| William Edward McKechnie | 男 | Independent Director | 79 | 未披露 | 8.12 | 2026-01-27 |
| Albert Reese Jr. | 男 | Independent Director | 77 | 未披露 | 5.39 | 2026-01-27 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Richard Christopher | 男 | Chief Executive Officer and Director | 57 | 61.25万美元 | 41.50 | 2026-01-27 |
| John Docherty | 男 | Chief Science Officer,Director and President | 57 | 52.35万美元 | 37.03 | 2026-01-27 |
| Michael Shankman | 男 | Chief Financial Officer | 66 | 24.84万美元 | 10.00 | 2026-01-27 |
董事简历
中英对照 | 中文 | 英文- Richard Christopher
-
Richard Christopher于2019年1月被任命为我们的首席财务官。此前，克里斯托弗先生于2016年12月至2019年1月担任iCAD，Inc.首席财务官。iCAD，Inc.是一家纳斯达克上市公司，专注于癌症的早期识别和治疗的疗法和解决方案。在iCAD，Inc.之前，Christopher先生于2014年3月至2016年12月担任Caliber Imaging&Diagnostics，Inc.的首席财务官，并于2015年10月至2016年12月担任首席运营官，该公司是一家专注于癌症检测成像解决方案的医疗技术公司，主要应用于皮肤科。在加入Caliber之前，Christopher先生从2000年开始在DusaPharmaceuticals，Inc.担任多个职责递增的职位，该公司是一家纳斯达克上市的皮肤科公司，专注于癌前皮肤病变的治疗，从2005年1月到2013年4月被Sun Pharmaceuticals Industries Ltd收购和整合，他最终担任首席财务官。Christopher先生拥有萨福克大学（Suffolk University）会计学理学硕士学位和宾利大学（Bentley University）金融学理学学士学位。
Richard Christopher joined Lexaria on August 31, 2024 to succeed Christopher Bunka as CEO, utilizing his extensive experience with pharmaceutical and medical device companies to further assist with the transition of Lexaria into the pharmaceutical sector. He was the Chief Financial Officer of InVivo Therapeutics Holdings Corp. ("InVivo") from 2019 to 2024. InVivo Therapeutics was a pioneering biomaterials and biotechnology company with a foc on the treatment of spinal cord injuries. Its goal was to develop and commercialize groundbreaking technologies and treatments for spinal cord injury (SCI). At the core of InVivo's technology portfolio was the Neuro Spinal Scaffold a novel and proprietary biomaterial that is implanted into the epicenter of the injury to modulate the healing environment and serve as a support for neuroregeneration. As the Neuro Spinal Scaffold failed to advance through clinical trials, InVivo delisted from the Nasdaq Stock Market around March 20, 2024. - Richard Christopher于2019年1月被任命为我们的首席财务官。此前，克里斯托弗先生于2016年12月至2019年1月担任iCAD，Inc.首席财务官。iCAD，Inc.是一家纳斯达克上市公司，专注于癌症的早期识别和治疗的疗法和解决方案。在iCAD，Inc.之前，Christopher先生于2014年3月至2016年12月担任Caliber Imaging&Diagnostics，Inc.的首席财务官，并于2015年10月至2016年12月担任首席运营官，该公司是一家专注于癌症检测成像解决方案的医疗技术公司，主要应用于皮肤科。在加入Caliber之前，Christopher先生从2000年开始在DusaPharmaceuticals，Inc.担任多个职责递增的职位，该公司是一家纳斯达克上市的皮肤科公司，专注于癌前皮肤病变的治疗，从2005年1月到2013年4月被Sun Pharmaceuticals Industries Ltd收购和整合，他最终担任首席财务官。Christopher先生拥有萨福克大学（Suffolk University）会计学理学硕士学位和宾利大学（Bentley University）金融学理学学士学位。
- Richard Christopher joined Lexaria on August 31, 2024 to succeed Christopher Bunka as CEO, utilizing his extensive experience with pharmaceutical and medical device companies to further assist with the transition of Lexaria into the pharmaceutical sector. He was the Chief Financial Officer of InVivo Therapeutics Holdings Corp. ("InVivo") from 2019 to 2024. InVivo Therapeutics was a pioneering biomaterials and biotechnology company with a foc on the treatment of spinal cord injuries. Its goal was to develop and commercialize groundbreaking technologies and treatments for spinal cord injury (SCI). At the core of InVivo's technology portfolio was the Neuro Spinal Scaffold a novel and proprietary biomaterial that is implanted into the epicenter of the injury to modulate the healing environment and serve as a support for neuroregeneration. As the Neuro Spinal Scaffold failed to advance through clinical trials, InVivo delisted from the Nasdaq Stock Market around March 20, 2024.
- Bal Bhullar
-
Bal Bhullar是一名特许专业会计师和注册总会计师，并持有Simon Fraser大学的CRM称号和British Columbia理工学院的财务管理文凭。Bhullar女士曾担任多个职位，包括BC风险管理协会（BC Risk Management Association of BC，并曾担任多个私人和上市公司的董事兼首席财务官，包括::ElectraMeccanica的首席财务官兼董事；Kismet Nutrials/American Electronic Commerce Solutions LLC的首席执行官/创始人；BKB Management Ltd.的首席执行官/创始人；以及Enertopia Corp.的顾问委员会成员。CSE:Top OTCQX:ENRT。此前，Bhullar女士曾担任Lexaria Corp CSE:LXX OTCQX:LXRP的首席财务官和董事。Enertopia Corp.CSE:Top OTCQX:ENRT。
Bal Bhullar is currently the CFO and Director of Damon Inc. OTCID:DMNIF and CEO/Founder/Director of BKB Management Ltd.Ms. Bhullar has proven expertise with increasing market capitalization, raising capital, overseeing corporate governance, SOX, ESG, diversity and regulatory compliance, financial & strategic planning, as ll as successfully completing initial public offerings, reverse mergers, biness expansions, start up operations, program development and product development.Ms. Bhullar is a Chartered Professional Accountant and Certified General Accountant, holds a CRM designation from Simon Fraser University and a diploma in Financial Management from British Columbia Institute of Technology. - Bal Bhullar是一名特许专业会计师和注册总会计师，并持有Simon Fraser大学的CRM称号和British Columbia理工学院的财务管理文凭。Bhullar女士曾担任多个职位，包括BC风险管理协会（BC Risk Management Association of BC，并曾担任多个私人和上市公司的董事兼首席财务官，包括::ElectraMeccanica的首席财务官兼董事；Kismet Nutrials/American Electronic Commerce Solutions LLC的首席执行官/创始人；BKB Management Ltd.的首席执行官/创始人；以及Enertopia Corp.的顾问委员会成员。CSE:Top OTCQX:ENRT。此前，Bhullar女士曾担任Lexaria Corp CSE:LXX OTCQX:LXRP的首席财务官和董事。Enertopia Corp.CSE:Top OTCQX:ENRT。
- Bal Bhullar is currently the CFO and Director of Damon Inc. OTCID:DMNIF and CEO/Founder/Director of BKB Management Ltd.Ms. Bhullar has proven expertise with increasing market capitalization, raising capital, overseeing corporate governance, SOX, ESG, diversity and regulatory compliance, financial & strategic planning, as ll as successfully completing initial public offerings, reverse mergers, biness expansions, start up operations, program development and product development.Ms. Bhullar is a Chartered Professional Accountant and Certified General Accountant, holds a CRM designation from Simon Fraser University and a diploma in Financial Management from British Columbia Institute of Technology.
- Christopher Bunka
-
Christopher Bunka自2006年以来一直担任董事会主席兼首席执行官，主要负责公司从较早的业务活动转向生物科学。Bunka先生是一位连续企业家，自1980年末以来一直在几家私营和上市公司工作。他作为印刷和广播电台的兼职商业评论员以及作家而闻名十多年。他在资本市场，公司治理，项目收购和公司融资方面拥有丰富的经验。他是该公司一些正在申请专利的发明家。自1988年以来，Bunka先生一直担任CAB Financial Services Ltd.的首席执行官，这是一家位于加拿大基洛纳的私人控股公司。他是一位风险投资家和企业顾问。
Christopher Bunka From 2006 until 2024 Mr. Bunka served many executive roles with Company, including CEO and CFO. Mr. Bunka continues to serve as Chairman of the Board, a role he has held since 2006 and as a strategic executive consultant to the Company. Mr. Bunka successfully transitioned the Company into the bioscience indtry during 2014 to 2016, after identifying the then unknown technology since named DehydraTECH. In 2020, Mr. Bunka directed the Company's up listing to the Nasdaq stock exchange. In 2023, he was the pivotal force focing the Company's energies towards DehydraTECH enhancement of GLP 1/GIP molecules for ight loss and diabetes control. Mr. Bunka repeatedly sced capital to fund corporate operations and develop DehydraTECH which has since undergone extensive laboratory, animal, and human clinical testing, including the Company's successfully completed Phase Ib human clinical trial investigating DehydraTECH enhanced GLP 1/GIP molecules in Atralia. Mr. Bunka is a named inventor on roughly half of the Company's current portfolio of 46 granted patents. - Christopher Bunka自2006年以来一直担任董事会主席兼首席执行官，主要负责公司从较早的业务活动转向生物科学。Bunka先生是一位连续企业家，自1980年末以来一直在几家私营和上市公司工作。他作为印刷和广播电台的兼职商业评论员以及作家而闻名十多年。他在资本市场，公司治理，项目收购和公司融资方面拥有丰富的经验。他是该公司一些正在申请专利的发明家。自1988年以来，Bunka先生一直担任CAB Financial Services Ltd.的首席执行官，这是一家位于加拿大基洛纳的私人控股公司。他是一位风险投资家和企业顾问。
- Christopher Bunka From 2006 until 2024 Mr. Bunka served many executive roles with Company, including CEO and CFO. Mr. Bunka continues to serve as Chairman of the Board, a role he has held since 2006 and as a strategic executive consultant to the Company. Mr. Bunka successfully transitioned the Company into the bioscience indtry during 2014 to 2016, after identifying the then unknown technology since named DehydraTECH. In 2020, Mr. Bunka directed the Company's up listing to the Nasdaq stock exchange. In 2023, he was the pivotal force focing the Company's energies towards DehydraTECH enhancement of GLP 1/GIP molecules for ight loss and diabetes control. Mr. Bunka repeatedly sced capital to fund corporate operations and develop DehydraTECH which has since undergone extensive laboratory, animal, and human clinical testing, including the Company's successfully completed Phase Ib human clinical trial investigating DehydraTECH enhanced GLP 1/GIP molecules in Atralia. Mr. Bunka is a named inventor on roughly half of the Company's current portfolio of 46 granted patents.
- John Docherty
-
John Docherty被任命为公司总裁，于2015年4月15日生效。在加入公司之前，Docherty先生是HELIX BIOPHARMACORP.的前总裁兼首席运营官。TSX:HBP，在那里他领导公司的植物和重组衍生的治疗性蛋白质候选产品的药物开发计划。Docherty先生是一位高级运营和管理执行官，在制药和生物制药领域拥有20多年的经验。他曾与大型跨国公司以及新兴的私营和上市初创企业合作。在Helix，Docherty先生还在投资者/利益相关者关系，资本筹集，资本市场发展，战略合作伙伴关系，监管机构互动和媒体关系领域发挥了重要作用，他还担任其董事会管理成员。在此之前，Docherty先生是Pharmaderm Laboratories Ltd.的总裁兼董事会成员，Pharmaderm Laboratories Ltd.是一家加拿大药物输送公司，开发了独特的微胶囊制剂技术，可用于一系列活性化合物。Docherty先生还曾在Astra Pharma Inc.，Nu-Pharm Inc.和Price Water House Coopers’；前全球制药行业咨询业务等公司任职。他是已发布专利和未决专利申请的指定发明人，并拥有理学硕士学位。药理学学士学位。多伦多大学毒理学博士学位。自2016年4月29日起担任公司董事。
John Docherty dedicates all of his professional time to Company and its subsidiaries serving as President of Lexaria since April 15, 2015 and as a director of Lexaria since April 29, 2016. In 2025 Mr. Docherty also assumed the position of Chief Science Officer for the Company. Prior to Lexaria, Mr. Docherty was former President and Chief Operating Officer of Helix BioPharma Corp. (TSX: HBP), where he led the company's pharmaceutical development programs for its plant and recombinantly derived therapeutic protein product candidates. Mr. Docherty is a senior operations and management executive with over 20 years' experience in the pharmaceutical and biopharmaceutical sectors. He has worked with large multinational companies and emerging, private and publicly held start ups. At Helix, Mr. Docherty was also instrumental in the areas of investor/stakeholder relations, capital raising, capital markets development, strategic partnering, regulatory authority interactions and media relations, and he also served as a management member of its Board of Directors. Prior to this, Mr. Docherty was President and a board member of PharmaDerm Laboratories Ltd., a Canadian drug delivery company that developed unique microencapsulation formulation technologies for e with a range of active compounds. - John Docherty被任命为公司总裁，于2015年4月15日生效。在加入公司之前，Docherty先生是HELIX BIOPHARMACORP.的前总裁兼首席运营官。TSX:HBP，在那里他领导公司的植物和重组衍生的治疗性蛋白质候选产品的药物开发计划。Docherty先生是一位高级运营和管理执行官，在制药和生物制药领域拥有20多年的经验。他曾与大型跨国公司以及新兴的私营和上市初创企业合作。在Helix，Docherty先生还在投资者/利益相关者关系，资本筹集，资本市场发展，战略合作伙伴关系，监管机构互动和媒体关系领域发挥了重要作用，他还担任其董事会管理成员。在此之前，Docherty先生是Pharmaderm Laboratories Ltd.的总裁兼董事会成员，Pharmaderm Laboratories Ltd.是一家加拿大药物输送公司，开发了独特的微胶囊制剂技术，可用于一系列活性化合物。Docherty先生还曾在Astra Pharma Inc.，Nu-Pharm Inc.和Price Water House Coopers’；前全球制药行业咨询业务等公司任职。他是已发布专利和未决专利申请的指定发明人，并拥有理学硕士学位。药理学学士学位。多伦多大学毒理学博士学位。自2016年4月29日起担任公司董事。
- John Docherty dedicates all of his professional time to Company and its subsidiaries serving as President of Lexaria since April 15, 2015 and as a director of Lexaria since April 29, 2016. In 2025 Mr. Docherty also assumed the position of Chief Science Officer for the Company. Prior to Lexaria, Mr. Docherty was former President and Chief Operating Officer of Helix BioPharma Corp. (TSX: HBP), where he led the company's pharmaceutical development programs for its plant and recombinantly derived therapeutic protein product candidates. Mr. Docherty is a senior operations and management executive with over 20 years' experience in the pharmaceutical and biopharmaceutical sectors. He has worked with large multinational companies and emerging, private and publicly held start ups. At Helix, Mr. Docherty was also instrumental in the areas of investor/stakeholder relations, capital raising, capital markets development, strategic partnering, regulatory authority interactions and media relations, and he also served as a management member of its Board of Directors. Prior to this, Mr. Docherty was President and a board member of PharmaDerm Laboratories Ltd., a Canadian drug delivery company that developed unique microencapsulation formulation technologies for e with a range of active compounds.
- Nicholas Baxter
-
Nicholas Baxter于2009年被任命为Lexaria Corp.董事会成员。巴克斯特先生于1975年获得利物浦大学理学学士学位，并在世界许多地区从事石油和天然气项目。自20世纪80年代以来，他一直在英国和加拿大的上市公司工作。巴克斯特先生作为董事会成员带来了丰富的现实世界经验。巴克斯特先生是公司审计与财务委员会，薪酬委员会以及公司治理与提名委员会的独立成员。
Nicholas Baxter joined the Board of Lexaria Corporation in 2009. He holds a Bachelor of Science (Hons.) in Geophysics from the University of Liverpool, graduating in 1975. He has since worked on a wide range of oil & gas, natural resces, and renewable energy projects in many parts of the world. Notably, in 1998, he spearheaded negotiations securing the first onshore oil & gas production sharing agreement with the State Oil Company of Azerbaijan. Since the 1980s, he has established and served as a CEO, officer, and director with companies in both the private and public markets in the U.K., the A and Canada, and has participated in numero financings to fund their growth. Mr. Baxter also serves on the board of Jericho Energy Ventures Inc., a TSX Venture Exchange listed company. - Nicholas Baxter于2009年被任命为Lexaria Corp.董事会成员。巴克斯特先生于1975年获得利物浦大学理学学士学位，并在世界许多地区从事石油和天然气项目。自20世纪80年代以来，他一直在英国和加拿大的上市公司工作。巴克斯特先生作为董事会成员带来了丰富的现实世界经验。巴克斯特先生是公司审计与财务委员会，薪酬委员会以及公司治理与提名委员会的独立成员。
- Nicholas Baxter joined the Board of Lexaria Corporation in 2009. He holds a Bachelor of Science (Hons.) in Geophysics from the University of Liverpool, graduating in 1975. He has since worked on a wide range of oil & gas, natural resces, and renewable energy projects in many parts of the world. Notably, in 1998, he spearheaded negotiations securing the first onshore oil & gas production sharing agreement with the State Oil Company of Azerbaijan. Since the 1980s, he has established and served as a CEO, officer, and director with companies in both the private and public markets in the U.K., the A and Canada, and has participated in numero financings to fund their growth. Mr. Baxter also serves on the board of Jericho Energy Ventures Inc., a TSX Venture Exchange listed company.
- William Edward McKechnie
-
William Edward McKechnie，自2016年9月起担任Lexaria Bioscience Corp.董事会成员。他是加拿大食品行业公认的思想领袖。在过去，McKechnie先生是Leaf 食品公司的总裁，Humpty Dumpty小吃食品公司的所有者和高级管理人员，百事可乐公司的高级领导。在作为专门从事食品制造的高管和营销人员的杰出职业生涯之后，他现在专注于推动加拿大食品行业走向未来。除了担任Food Starter的董事会主席，McKechnie先生也是the Davies Group和William Davies Consulting Inc.的主席/首席执行官。他也是Advanced Technology for Food Manufacturing的董事会主席，并担任St Jerome's大学的董事会成员。McKechnie先生被授予Philip Morris主席奖，以表彰“对公司产生重大和持久影响的杰出贡献”。
William Edward McKechnie is a ll recognized thought leader in the Canadian food indtry. In the past, Mr. McKechnie was president of Maple Leaf Foods, an owner and president at Humpty Dumpty and a senior leader at PepsiCo & Kraft Heinz General Foods. After a distinguished career as an executive and marketer specializing in food manufacturing, he now foces on moving the Canadian food sector into the future. Besides being the former chairman of Food Starter's board, Mr. McKechnie is also the Chairman/CEO of The Davies Group and William Davies Consulting Inc. Mr. McKechnie is also a chairman of the board for Advanced Technology For Food Manufacturing and formerly served on the Board Of Governors for St Jeromes University. Mr. McKechnie was awarded Philip Morris Chairman's Award for "recognition of extraordinary contributions having a significant and lasting impact on the Corporation". - William Edward McKechnie，自2016年9月起担任Lexaria Bioscience Corp.董事会成员。他是加拿大食品行业公认的思想领袖。在过去，McKechnie先生是Leaf 食品公司的总裁，Humpty Dumpty小吃食品公司的所有者和高级管理人员，百事可乐公司的高级领导。在作为专门从事食品制造的高管和营销人员的杰出职业生涯之后，他现在专注于推动加拿大食品行业走向未来。除了担任Food Starter的董事会主席，McKechnie先生也是the Davies Group和William Davies Consulting Inc.的主席/首席执行官。他也是Advanced Technology for Food Manufacturing的董事会主席，并担任St Jerome's大学的董事会成员。McKechnie先生被授予Philip Morris主席奖，以表彰“对公司产生重大和持久影响的杰出贡献”。
- William Edward McKechnie is a ll recognized thought leader in the Canadian food indtry. In the past, Mr. McKechnie was president of Maple Leaf Foods, an owner and president at Humpty Dumpty and a senior leader at PepsiCo & Kraft Heinz General Foods. After a distinguished career as an executive and marketer specializing in food manufacturing, he now foces on moving the Canadian food sector into the future. Besides being the former chairman of Food Starter's board, Mr. McKechnie is also the Chairman/CEO of The Davies Group and William Davies Consulting Inc. Mr. McKechnie is also a chairman of the board for Advanced Technology For Food Manufacturing and formerly served on the Board Of Governors for St Jeromes University. Mr. McKechnie was awarded Philip Morris Chairman's Award for "recognition of extraordinary contributions having a significant and lasting impact on the Corporation".
- Albert Reese Jr.
-
小艾尔·里斯（Al Reese Jr.）已同意在本次发行结束后加入董事会。Reese先生在公共和私人企业拥有40多年的经验，并曾在能源公司和商业银行担任董事会职务。他曾担任数十亿公共能源公司的首席财务官，并指导了50多项收购和融资，规模从几十万美元到数十亿美元不等。Reese先生从1999年到2014年担任ATP Oil and Gas的首席财务官，在此期间，他指导ATP进行了总计超过100亿美元的股权，债务和夹层交易。Reese先生于1971年获得德克萨斯农工大学工商管理金融学学士学位，并于1977年获得休斯敦大学工商管理硕士学位，是一名注册会计师。
Albert Reese Jr. has over 40 years of experience in public and private binesses including as CFO of a formerly Nasdaq listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20 year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018. He currently serves as an Independent Director and Chairman of the Audit Committee for a privately held insurance company headquartered in The Woodlands, Texas. In October 2024, Mr. Reese became an Independent Director, member of the Executive Committee and Chairman of the Audit Committee for a newly chartered community bank in Texas. Mr. Reese is also President and Chairman of a family charitable 501(c) 3 foundation and Interim Chairman of a charitable 501(c) 3 entity that foc on Bible literacy.Mr. Reese is a Certified Public Accountant (1974), received his Bachelor of Biness Administration degree from Texas A&M University in 1971, and his MBA from University of Hoton in 1977. He has extensive experience at a senior level in financial services, finance transactions, investor relations, and more. - 小艾尔·里斯（Al Reese Jr.）已同意在本次发行结束后加入董事会。Reese先生在公共和私人企业拥有40多年的经验，并曾在能源公司和商业银行担任董事会职务。他曾担任数十亿公共能源公司的首席财务官，并指导了50多项收购和融资，规模从几十万美元到数十亿美元不等。Reese先生从1999年到2014年担任ATP Oil and Gas的首席财务官，在此期间，他指导ATP进行了总计超过100亿美元的股权，债务和夹层交易。Reese先生于1971年获得德克萨斯农工大学工商管理金融学学士学位，并于1977年获得休斯敦大学工商管理硕士学位，是一名注册会计师。
- Albert Reese Jr. has over 40 years of experience in public and private binesses including as CFO of a formerly Nasdaq listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20 year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018. He currently serves as an Independent Director and Chairman of the Audit Committee for a privately held insurance company headquartered in The Woodlands, Texas. In October 2024, Mr. Reese became an Independent Director, member of the Executive Committee and Chairman of the Audit Committee for a newly chartered community bank in Texas. Mr. Reese is also President and Chairman of a family charitable 501(c) 3 foundation and Interim Chairman of a charitable 501(c) 3 entity that foc on Bible literacy.Mr. Reese is a Certified Public Accountant (1974), received his Bachelor of Biness Administration degree from Texas A&M University in 1971, and his MBA from University of Hoton in 1977. He has extensive experience at a senior level in financial services, finance transactions, investor relations, and more.
高管简历
中英对照 | 中文 | 英文- Richard Christopher
Richard Christopher于2019年1月被任命为我们的首席财务官。此前，克里斯托弗先生于2016年12月至2019年1月担任iCAD，Inc.首席财务官。iCAD，Inc.是一家纳斯达克上市公司，专注于癌症的早期识别和治疗的疗法和解决方案。在iCAD，Inc.之前，Christopher先生于2014年3月至2016年12月担任Caliber Imaging&Diagnostics，Inc.的首席财务官，并于2015年10月至2016年12月担任首席运营官，该公司是一家专注于癌症检测成像解决方案的医疗技术公司，主要应用于皮肤科。在加入Caliber之前，Christopher先生从2000年开始在DusaPharmaceuticals，Inc.担任多个职责递增的职位，该公司是一家纳斯达克上市的皮肤科公司，专注于癌前皮肤病变的治疗，从2005年1月到2013年4月被Sun Pharmaceuticals Industries Ltd收购和整合，他最终担任首席财务官。Christopher先生拥有萨福克大学（Suffolk University）会计学理学硕士学位和宾利大学（Bentley University）金融学理学学士学位。
Richard Christopher joined Lexaria on August 31, 2024 to succeed Christopher Bunka as CEO, utilizing his extensive experience with pharmaceutical and medical device companies to further assist with the transition of Lexaria into the pharmaceutical sector. He was the Chief Financial Officer of InVivo Therapeutics Holdings Corp. ("InVivo") from 2019 to 2024. InVivo Therapeutics was a pioneering biomaterials and biotechnology company with a foc on the treatment of spinal cord injuries. Its goal was to develop and commercialize groundbreaking technologies and treatments for spinal cord injury (SCI). At the core of InVivo's technology portfolio was the Neuro Spinal Scaffold a novel and proprietary biomaterial that is implanted into the epicenter of the injury to modulate the healing environment and serve as a support for neuroregeneration. As the Neuro Spinal Scaffold failed to advance through clinical trials, InVivo delisted from the Nasdaq Stock Market around March 20, 2024.- Richard Christopher于2019年1月被任命为我们的首席财务官。此前，克里斯托弗先生于2016年12月至2019年1月担任iCAD，Inc.首席财务官。iCAD，Inc.是一家纳斯达克上市公司，专注于癌症的早期识别和治疗的疗法和解决方案。在iCAD，Inc.之前，Christopher先生于2014年3月至2016年12月担任Caliber Imaging&Diagnostics，Inc.的首席财务官，并于2015年10月至2016年12月担任首席运营官，该公司是一家专注于癌症检测成像解决方案的医疗技术公司，主要应用于皮肤科。在加入Caliber之前，Christopher先生从2000年开始在DusaPharmaceuticals，Inc.担任多个职责递增的职位，该公司是一家纳斯达克上市的皮肤科公司，专注于癌前皮肤病变的治疗，从2005年1月到2013年4月被Sun Pharmaceuticals Industries Ltd收购和整合，他最终担任首席财务官。Christopher先生拥有萨福克大学（Suffolk University）会计学理学硕士学位和宾利大学（Bentley University）金融学理学学士学位。
- Richard Christopher joined Lexaria on August 31, 2024 to succeed Christopher Bunka as CEO, utilizing his extensive experience with pharmaceutical and medical device companies to further assist with the transition of Lexaria into the pharmaceutical sector. He was the Chief Financial Officer of InVivo Therapeutics Holdings Corp. ("InVivo") from 2019 to 2024. InVivo Therapeutics was a pioneering biomaterials and biotechnology company with a foc on the treatment of spinal cord injuries. Its goal was to develop and commercialize groundbreaking technologies and treatments for spinal cord injury (SCI). At the core of InVivo's technology portfolio was the Neuro Spinal Scaffold a novel and proprietary biomaterial that is implanted into the epicenter of the injury to modulate the healing environment and serve as a support for neuroregeneration. As the Neuro Spinal Scaffold failed to advance through clinical trials, InVivo delisted from the Nasdaq Stock Market around March 20, 2024.
- John Docherty
John Docherty被任命为公司总裁，于2015年4月15日生效。在加入公司之前，Docherty先生是HELIX BIOPHARMACORP.的前总裁兼首席运营官。TSX:HBP，在那里他领导公司的植物和重组衍生的治疗性蛋白质候选产品的药物开发计划。Docherty先生是一位高级运营和管理执行官，在制药和生物制药领域拥有20多年的经验。他曾与大型跨国公司以及新兴的私营和上市初创企业合作。在Helix，Docherty先生还在投资者/利益相关者关系，资本筹集，资本市场发展，战略合作伙伴关系，监管机构互动和媒体关系领域发挥了重要作用，他还担任其董事会管理成员。在此之前，Docherty先生是Pharmaderm Laboratories Ltd.的总裁兼董事会成员，Pharmaderm Laboratories Ltd.是一家加拿大药物输送公司，开发了独特的微胶囊制剂技术，可用于一系列活性化合物。Docherty先生还曾在Astra Pharma Inc.，Nu-Pharm Inc.和Price Water House Coopers’；前全球制药行业咨询业务等公司任职。他是已发布专利和未决专利申请的指定发明人，并拥有理学硕士学位。药理学学士学位。多伦多大学毒理学博士学位。自2016年4月29日起担任公司董事。
John Docherty dedicates all of his professional time to Company and its subsidiaries serving as President of Lexaria since April 15, 2015 and as a director of Lexaria since April 29, 2016. In 2025 Mr. Docherty also assumed the position of Chief Science Officer for the Company. Prior to Lexaria, Mr. Docherty was former President and Chief Operating Officer of Helix BioPharma Corp. (TSX: HBP), where he led the company's pharmaceutical development programs for its plant and recombinantly derived therapeutic protein product candidates. Mr. Docherty is a senior operations and management executive with over 20 years' experience in the pharmaceutical and biopharmaceutical sectors. He has worked with large multinational companies and emerging, private and publicly held start ups. At Helix, Mr. Docherty was also instrumental in the areas of investor/stakeholder relations, capital raising, capital markets development, strategic partnering, regulatory authority interactions and media relations, and he also served as a management member of its Board of Directors. Prior to this, Mr. Docherty was President and a board member of PharmaDerm Laboratories Ltd., a Canadian drug delivery company that developed unique microencapsulation formulation technologies for e with a range of active compounds.- John Docherty被任命为公司总裁，于2015年4月15日生效。在加入公司之前，Docherty先生是HELIX BIOPHARMACORP.的前总裁兼首席运营官。TSX:HBP，在那里他领导公司的植物和重组衍生的治疗性蛋白质候选产品的药物开发计划。Docherty先生是一位高级运营和管理执行官，在制药和生物制药领域拥有20多年的经验。他曾与大型跨国公司以及新兴的私营和上市初创企业合作。在Helix，Docherty先生还在投资者/利益相关者关系，资本筹集，资本市场发展，战略合作伙伴关系，监管机构互动和媒体关系领域发挥了重要作用，他还担任其董事会管理成员。在此之前，Docherty先生是Pharmaderm Laboratories Ltd.的总裁兼董事会成员，Pharmaderm Laboratories Ltd.是一家加拿大药物输送公司，开发了独特的微胶囊制剂技术，可用于一系列活性化合物。Docherty先生还曾在Astra Pharma Inc.，Nu-Pharm Inc.和Price Water House Coopers’；前全球制药行业咨询业务等公司任职。他是已发布专利和未决专利申请的指定发明人，并拥有理学硕士学位。药理学学士学位。多伦多大学毒理学博士学位。自2016年4月29日起担任公司董事。
- John Docherty dedicates all of his professional time to Company and its subsidiaries serving as President of Lexaria since April 15, 2015 and as a director of Lexaria since April 29, 2016. In 2025 Mr. Docherty also assumed the position of Chief Science Officer for the Company. Prior to Lexaria, Mr. Docherty was former President and Chief Operating Officer of Helix BioPharma Corp. (TSX: HBP), where he led the company's pharmaceutical development programs for its plant and recombinantly derived therapeutic protein product candidates. Mr. Docherty is a senior operations and management executive with over 20 years' experience in the pharmaceutical and biopharmaceutical sectors. He has worked with large multinational companies and emerging, private and publicly held start ups. At Helix, Mr. Docherty was also instrumental in the areas of investor/stakeholder relations, capital raising, capital markets development, strategic partnering, regulatory authority interactions and media relations, and he also served as a management member of its Board of Directors. Prior to this, Mr. Docherty was President and a board member of PharmaDerm Laboratories Ltd., a Canadian drug delivery company that developed unique microencapsulation formulation technologies for e with a range of active compounds.
- Michael Shankman
Michael Shankman，2024年10月1日加入公司担任首席财务官。Shankman先生曾于2023年6月至2024年2月期间通过NowCFO被公司聘为外包CFO。他是一名注册会计师，拥有加州州立大学金融学MBA学位，此前曾在2021年至2024年期间与NOW CFO合作。在担任NOW首席财务官期间，Shankman先生提供了外包的首席财务官和财务总监服务，从而在广泛的行业领域获得了丰富的经验和对上市公司和私营公司的熟悉。在与NOW CFO接触之前，Shankman先生曾在Arcticom Group工作，该公司是一家价值1.6亿美元的供应商，为全国杂货连锁店提供制冷和暖通空调设计、安装、维护和维修服务，并在2020-2021年期间担任公司控制人。从2019年到2020年，Shankman先生是Change.org一家价值3500万美元的公益公司的控制人。
Michael Shankman joined Lexaria on October 1, 2024 as its Chief Financial Officer, filling the vacancy created by the resignation of Nelson Cabatuan. Mr. Shankman was previoly engaged by the Company as an outsced CFO via NowCFO from June 2023 to February 2024. Mr. Shankman is a Certified Public Accountant holding an MBA, Finance from California State University who previoly worked with NOW CFO from 2021 to 2024. During his time with NOW CFO, Mr. Shankman provided outsced CFO and Controller services gaining extensive experience and familiarity with both public and private companies in a wide variety of industry fields. Prior to his engagement with NOW CFO, Mr. Shankman was the Corporate Controller for The Arcticom Group, a $160M provider of refrigeration and HVAC design, installation, maintenance and repair services to national grocery chains, from 2020 2021. And from 2019 to 2020 Mr. Shankman was the Controller for Change.Org, a $35M public benefit corporation.- Michael Shankman，2024年10月1日加入公司担任首席财务官。Shankman先生曾于2023年6月至2024年2月期间通过NowCFO被公司聘为外包CFO。他是一名注册会计师，拥有加州州立大学金融学MBA学位，此前曾在2021年至2024年期间与NOW CFO合作。在担任NOW首席财务官期间，Shankman先生提供了外包的首席财务官和财务总监服务，从而在广泛的行业领域获得了丰富的经验和对上市公司和私营公司的熟悉。在与NOW CFO接触之前，Shankman先生曾在Arcticom Group工作，该公司是一家价值1.6亿美元的供应商，为全国杂货连锁店提供制冷和暖通空调设计、安装、维护和维修服务，并在2020-2021年期间担任公司控制人。从2019年到2020年，Shankman先生是Change.org一家价值3500万美元的公益公司的控制人。
- Michael Shankman joined Lexaria on October 1, 2024 as its Chief Financial Officer, filling the vacancy created by the resignation of Nelson Cabatuan. Mr. Shankman was previoly engaged by the Company as an outsced CFO via NowCFO from June 2023 to February 2024. Mr. Shankman is a Certified Public Accountant holding an MBA, Finance from California State University who previoly worked with NOW CFO from 2021 to 2024. During his time with NOW CFO, Mr. Shankman provided outsced CFO and Controller services gaining extensive experience and familiarity with both public and private companies in a wide variety of industry fields. Prior to his engagement with NOW CFO, Mr. Shankman was the Corporate Controller for The Arcticom Group, a $160M provider of refrigeration and HVAC design, installation, maintenance and repair services to national grocery chains, from 2020 2021. And from 2019 to 2020 Mr. Shankman was the Controller for Change.Org, a $35M public benefit corporation.